NCT03587298

Brief Summary

The aim of this study is to test a non-invasive imaging technique to reliably diagnose NAFLD in children and adolescents with obesity and assess the degree of fibrosis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2018

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 2, 2018

Completed
14 days until next milestone

First Posted

Study publicly available on registry

July 16, 2018

Completed
2 months until next milestone

Study Start

First participant enrolled

September 15, 2018

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2021

Completed
Last Updated

March 10, 2021

Status Verified

March 1, 2021

Enrollment Period

2.8 years

First QC Date

July 2, 2018

Last Update Submit

March 9, 2021

Conditions

Keywords

ShearWave Elastography

Outcome Measures

Primary Outcomes (1)

  • Assess non-alcoholic fatty liver disease in adolescents and children with obesity by use of shear wave elastography

    stiffness (in kilopascals) of the liver measured with real-time shear wave elastography (RT-SWE) and hence regarding the amount of fibrosis in chronic liver disease

    12 month

Study Arms (2)

Group 1

NAFLK criteria met (by definition: sonographic fatty liver)

Procedure: Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)

Group 2

Control group: matched age; no NAFKL

Procedure: Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)

Interventions

The SWE is carried out intercostally. If possible, the patient should hold the breath for 5-10 seconds. So-called colour charts are used, which indicate the derived liver stiffness in colour-coded form. In addition to the visual assessment of these colour charts, the quantitative ROI-based measurement of the SWE in kPa is performed in the "hardest" appearing areas. The measurement is performed at 5 different sites of the liver parenchyma and all SWE values are recorded.

Group 1Group 2

Eligibility Criteria

Age6 Years - 18 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

The patient group is recruited from the obesity consultation hour as well as the emergency consultation hour and the wards of the Clinic for Paediatrics and Youth Medicine at the University Hospital Aachen. The control group is recruited from the group of outpatients and inpatients receiving abdominal sonography from another indication and show no sonographic or laboratory chemical evidence of NAFLD. Patients in the control group are evaluated once.

You may qualify if:

  • male and male children and adolescents aged 6-18 years
  • obesity with a BMI above percentile 95 according to Kromeyer-Hauschild
  • NAFLD criteria met (by definition: sonographic fatty liver)
  • written informed consent
  • patients of matching age are included in the control group without any indication of NAFLD

You may not qualify if:

  • other chronic liver diseases
  • alcohol consumption (more than 20g for girls and 30g for boys per day), after explicit anamnesis
  • persons who are accommodated in an institution by court or official order

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Paediatric Clini; RWTH Aachen University Hospital

Aachen, North Rhine-Westphalia, 52074, Germany

RECRUITING

MeSH Terms

Conditions

Non-alcoholic Fatty Liver Disease

Condition Hierarchy (Ancestors)

Fatty LiverLiver DiseasesDigestive System Diseases

Study Officials

  • Angeliki Pappas, Dr. med.

    Paediatric Clinic; RWTH Aachen University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Angeliki Pappas, Dr. med.

CONTACT

Evangelia-Vera Papagrigoraki

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 2, 2018

First Posted

July 16, 2018

Study Start

September 15, 2018

Primary Completion

July 1, 2021

Study Completion

August 1, 2021

Last Updated

March 10, 2021

Record last verified: 2021-03

Locations